文献速递消化系统肿瘤

射频消融对比立体定向放疗治疗不可手术早期肝细胞癌:美国国家癌症数据库分析

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
PubMed 文献 · J Clin Oncol · 2018-01-12

基于美国国家癌症数据库的观察性研究比较RFA与SBRT在不可手术I/II期HCC患者中的疗效。共3684例(92.6%)接受RFA、296例(7.4%)接受SBRT。倾向评分匹配后RFA组5年总生存为29.8%(95%CI 24.5%–35.3%),SBRT组为19.3%(95%CI 13.5%–25.9%),P<.001,RFA在各亚组及严重纤维化/肝硬化情况下获益一致。

要点

  • 不可手术I/II期HCC中RFA的5年总生存优于SBRT。
  • RFA获益在全部 examined 亚组中一致,且不受严重纤维化/肝硬化影响。
  • 结果受回顾性设计偏倚限制,无随机试验时应参考本结果选择局部消融。

核心结论

  • 对于不可手术管理的I期或II期肝细胞癌患者,RFA治疗较SBRT获得更优的总生存。

研究设计与样本

  • 观察性研究,使用美国国家癌症数据库比较RFA与SBRT在不可手术I/II期HCC患者中的有效性。
  • 共纳入3684例(92.6%)接受RFA和296例(7.4%)接受SBRT的患者。
  • 采用倾向评分加权和倾向评分匹配分析,基于患者、机构和肿瘤层面特征比较总生存。

主要发现

  • 倾向匹配后RFA组5年总生存为29.8%(95%CI 24.5%–35.3%),SBRT组为19.3%(95%CI 13.5%–25.9%),P<.001。
  • 逆概率加权分析得到相似结果。
  • RFA的生存获益在所有 examined 亚组中一致,且对严重纤维化/肝硬化效应稳健。

临床怎么用

  • 在缺乏随机临床试验的情况下,为不可手术局部HCC推荐局部消融治疗时可考虑本研究发现。
  • RFA可能作为不可手术I/II期HCC的优先局部消融选择之一。

局限性

  • 结果受回顾性研究设计相关偏倚的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Data that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data for these treatment modalities, we aimed to compare the effectiveness of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) by using the National Cancer Database. Methods We conducted an observational study to compare the effectiveness of RFA versus SBRT in nonsurgically managed patients with stage I or II HCC. Overall survival was compared by using propensity score-weighted and propensity score-matched analyses based on patient-, facility-, and tumor-level characteristics. A sensitivity analysis was performed to evaluate the effect of severe fibrosis/cirrhosis. In addition, we performed exploratory analyses to determine the effectiveness of RFA and SBRT in clinically relevant patient subsets. Results Overall, 3,684 (92.6%) and 296 (7.4%) nonsurgically managed patients with stage I or II HCC received RFA or SBRT, respectively. After propensity matching, 5-year overall survival was 29.8% (95% CI, 24.5% to 35.3%) in the RFA group versus 19.3% (95% CI, 13.5% to 25.9%) in the SBRT group ( P < .001). Inverse probability-weighted analysis yielded similar results. The benefit of RFA was consistent across all subgroups examined and was robust to the effects of severe fibrosis/cirrhosis. Conclusion Our study suggests that treatment with RFA yields superior survival compared with SBRT for nonsurgically managed patients with stage I or II HCC. Even though our results are limited by the biases related to the retrospective study design, we believe that, in the absence of a randomized clinical trial, our findings should be considered when recommending local ablative therapy for localized unresectable HCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rajyaguru DJ, Borgert AJ, Smith AL, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database. J Clin Oncol. 2018. PMID: 29328861. doi:10.1200/JCO.2017.75.3228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。